The general treatment of advanced HER2-positive breast cancer has typically consisted of a combination of chemotherapy and the monoclonal antibodies trastuzumab and pertuzumab as a first-line treatment, and the antibody-drug conjugate T-DM1 in the second line.
“Once these treatments were incorporated into the management of metastatic disease the outcomes of patients improved substantially,” said Ian Krop, MD, PhD, associate chief of the Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute in Boston.
